All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
CAT | Product Name | Target Species | Antibody Clone | Antibody Host | Receptor Construction | Vector Type | Targeting Cell Type | CAR Vector Type | Inquiry & Datasheet |
CAR-YJ137 | Anti-LRPAP1 (7F1) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | 7F1 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
CAR-YJ138 | Anti-LRPAP1 (8G8) h(41BB-CD3ζ) CAR, pCDCAR1 | Human, Mouse | 8G8 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
CAR-YJ139 | Anti-LRPAP1 (9L447) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | 9L447 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
CAR-YJ140 | Anti-LRPAP1 (AT8G8) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | AT8G8 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
CAR-YJ637 | Anti-LRPAP1 (7F1) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | 7F1 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
CAR-YJ638 | Anti-LRPAP1 (8G8) h(CD28-CD3ζ) CAR, pCDCAR1 | Human, Mouse | 8G8 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
CAR-YJ639 | Anti-LRPAP1 (9L447) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | 9L447 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
CAR-YJ640 | Anti-LRPAP1 (AT8G8) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | AT8G8 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
XS-1222-ZP910 | LRPAP1 (LRP1 Receptor) h(CD28-CD3ζ) Ligand-based CAR, pCDCAR1 | Human | LRPAP1-CD28-CD6ζ | Lentiviral vector | T cell | ||||
XS-1222-ZP2310 | LRPAP1 (LRP1 Receptor) h(41BB-CD3ζ) Ligand-based CAR, pCDCAR1 | Human | LRPAP1-41BB-CD6ζ | Lentiviral vector | T cell |
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION